The need for assay methods of sufficient sensitivity to determine the low concentrations of hormones present in body fluids led to the original development of immunoassays and analogous "binding" (or "ligand") assays in the late 1950s and early 1960s. These methods depend on the use of a binding agent (also commonly referred to by other terms such as "receptor," "binding reagent," and "analyte-specific reagent"), a substance used to recognize and bind the target analyte. Typical binding agents include antibodies, antigens, cell receptors, and serum binding proteins. Immunoassays still constitute the most widely used class of binding assays, although microarray-based nucleic acid assays, employing oligonucleotides as binding agents, are rapidly increasing in popularity.
A principal objective in this field since the emergence of these assays has been to increase their sensitivities, especially in their application to certain analytes. Typifying such attempts, Rissin et al. (1 ) have recently reported a new approach to the further improvement of immunoassay sensitivities, claiming that with the use of an ELISA-type system, they were able to "detect serum proteins at subfemtomolar concentrations" and to increase the sensitivity of measurements "using a typical ELISA plate reader by a factor of about 68 000."
But before discussing the novel features of Rissin et al.'s approach, we should briefly examine the concept of sensitivity and the meaning of the term "sensitive" to describe the performance of a binding assay-or indeed that of any measurement system. Many workers in this area, including Rissin et al., identify sensitivity with the lower limit of detection (LoD) 3 of an assay. However, certain bodies, including the American Chemical Society and the International Union of Pure and Applied Chemistry, have formally defined sensitivity as the slope of the dose-response curve [or the response/dose (R/D) ratio-an intrinsically meaningless concept with which we strongly disagree (see Fig. 1 )].
The reason for our opposition to this concept is, in short, that the more sensitive of 2 or more systems has been regarded by scientists since the 1850s as the system that detects and measures the smaller amount of that which the systems are intended to measure, i.e., the system that exhibits the lower LoD. Though some have argued (2 ) that increasing the response-curve slope reduces the LoD, this supposition is not generally true.
The fundamental difference between these 2 concepts of sensitivity has not only led to past controversy and debate (3 ), but the slope concept has also profoundly influenced the design of immunoassays and analogous methods. Equating sensitivity with the response-curve slope or the R/D ratio has, in practice, led to the use of relatively high antibody concentrations, typically approximating 1/K (where K is the affinity constant governing the binding reaction under the conditions used in the assay) in competitive assays (e.g., RIAs) and 20/K in noncompetitive immunometric methods (e.g., sandwich assays), this generally implying the capture of approximately 40%-50% and 90%, respectively, of the analyte in a sample. (Note that immunoassays that rely on the use of radioisotopically labeled antibodies are generally termed IRMAs but are sometimes of competitive design.)
But an important factor that affects an assay's LoD is the presence of noise in the system, i.e., the variation in the signal generated by a blank sample containing 0 analyte, generally represented by the SD of the blank measurement. Thus a key determinant of an assay's LoD (as of any measuring system) is the signal/noise ratio, where "signal" here refers to the signal deriving from the target analyte. Clearly the lower the analyte concentration, the lower the signal/noise ratio, it being commonly accepted that a ratio of 3 defines the LoD.
Rissin et al. clearly recognize the importance of maximizing the signal/noise ratio to maximize immunoassay sensitivity. Their approach to achieving this objective (termed digital ELISA) is to count individual target molecules that are captured by antibody on a solid support (this support comprising thousands of microscopic beads, each 2.7 m in diameter), the captured molecules being subsequently bound by a second, enzyme-labeled antibody to form an antigen/antibody sandwich. By using large numbers of beads, the authors ensure both that a high proportion (approximately 70%) of analyte molecules in a sample is cap-tured and that most beads capture only a single analyte molecule.
Following the beads' exposure to the sample and to the labeled antibody, they are placed in contact with an array of femto-sized wells into which approximately 10%-15% of the beads become trapped. These trapped beads are then exposed to a fluorogenic substrate, which causes fluorescence to be generated in the immediate vicinity of the beads that bear enzyme-labeled complexes, thus creating countable pinpoints of light.
The strategy of counting target analyte molecules to which labeled antibody is bound (as opposed to measuring the total signal generated by an aggregate of target molecules as in conventional ELISAs) has much, in principle, to commend it. For example, in an assay that requires measurement of fluorescent signals, background noise may be created by the instruments used to detect the fluorescence, the support matrix on which captured analyte molecules are located, and the nonspecific binding of labeled antibodies. Counting of individual molecules to which a fluorogenic enzyme is attached reduces some-though not all-of the noise from these sources.
So, have Rissin et al. succeeded in their aim, and transformed the immunodiagnostics field by developing a method capable of determining subfemtomolar protein concentrations?
First it must be noted that similar sensitivity claims were made for 2 methods described in reports published some 30 years ago (4, 5 ) . Both methods relied on enzymes as signal amplifiers. One of these methods, which used a fluorogenic substrate and fluorescence , an LoD that was some 1000-fold lower than the LoDs of both an RIA and of a conventional ELISA that relied on color measurement. In short, both methods yielded sensitivities (as indicated by their LoDs) considerably superior to those achieved by Rissin et al.
In addition, both of these older assays employed reagents and methods within the compass of a competent biochemist, albeit requiring measuring instruments (i.e., a fluorometer and liquid scintillation counter, respectively) not found in every laboratory.
One might therefore ask: why did these reports, and the methods described therein, not attract the attention now accorded to the report by Rissin et al.? Although the reasons must remain a subject of conjecture, we believe the principal reason for the lack of interest in these methods was that they were simply ahead of their time. Both labeled antibody and ELISA methods were proposed in the late 1960s, but more than 10 years later the only labeled antibody method in common use was an assay for hepatitis-B antigen; indeed, doubts still persisted regarding the relative sensitivities of RIAs and IRMAs.
Moreover, factors other than sensitivity (e.g., precision, working range, performance time, and cost) are also relevant to an assay system's clinical utility. Of in- creasing importance in this context is the ability to simultaneously assay multiple analytes in the same sample, primarily because knowledge of their concentrations may be of clinical importance per se. But most clinically important analytes (e.g., hormones such as human chorionic gonadotropin, thyroid-stimulating hormone, and human growth hormone) are of heterogeneous molecular composition, comprising (variable) mixtures of isoforms, each differing in molecular structure and (potentially) in biological activity in vivo.
However, assays of analytes that differ between samples-termed "comparative" in the 1950s by Gaddum (6 ) and Finney (7 )-are inevitably method dependent and cannot be standardized. Thus, results yielded by different immunoassays of such analytes typically differ, as do those between immunoassays and bioassays. Hence only determination of the amount and biological activity of each molecular species contained in a heterogeneous analyte can, in principle, provide a valid representation of the total in vivo biological activity of the analyte in a sample.
Recognition of this issue led to the establishment of an IFCC project and working group (which has since published reports of its activities in Clinical Chemistry) on the standardization of human chorionic gonadotropin measurements after a presentation by one of us (R. Ekins) on immunoassay standardization at the 3rd Bergmeyer Conference on Assay Results in Life Sciences in 1990. This presentation highlighted the clinical need for an ultrasensitive method that would permit simultaneous assay of the multiple isoforms that characterize many polypeptide hormones. Indeed, this need had been an important factor in the original development of microspot array-based binding assays (now termed microarray methods) in the late 1980s (8 ) . These methods are based on the concept of ambient analyte assay (i.e., an assay in which the bindingagent concentration employed is Ͻ0.1/K, and ideally Ͻ0.01/K, binding Ͻ9.1% and Ͻ1%, respectively, of the analyte present in the sample).
Such assays are, among other things, independent of sample volume. Counterintuitively, however, they also require shorter incubation times and can yield higher sensitivities than conventional binding assays. To achieve these objectives, fluorescent microspheres have been used as signal amplifiers and binding agents located at high surface density within micropots on solid supports as molecular monolayers, thereby minimizing background noise.
In practice (using antibodies of a low affinity of 10 7 L/mol and confocal microscopy to scan arrays) sensitivities of 8 ϫ 10 5 thyroid-stimulating hormone molecules/mL or approximately 1.4 fmol/L were achieved by one of us (R. Ekins) in preliminary studies (9 ) , albeit using overnight incubations. But by using improved fluorescent microspheres and scanning equipment, and higher-affinity antibodies (or other binding agents), sensitivities of 1000 molecules/mL, i.e., approximately 1.7 amol/L, have been achieved by Boehringer Mannheim researchers-again a greater sensitivity than yielded by Rissin et al.'s approach. (Note that the microspheres used in this context must be nonsticky; hence, Boehringer Mannheim synthesized its own spheres to achieve this end. Note also that Boehringer Mannheim nevertheless elected to sacrifice ultrahigh sensitivity in the interests of a reduction in overall assay performance times [to 15 min] while retaining a sensitivity deemed to be adequate for most clinical purposes.)
Thus, in summary-and notwithstanding its admirable ingenuity, novelty, and high sensitivity-the method of Rissin et al.
(1 ) has yet to match the advantages of existing microarray methods, particularly their ability to simultaneously determine a multiplicity of target analytes in a sample.
